Details

Autor(en) / Beteiligte

• Sakamoto, Yasutoshi
• Bando, Hideaki
• Nakamura, Yoshiaki
• Hasegawa, Hiromi
• Kuwaki, Takako
• Okamoto, Wataru
• Taniguchi, Hiroya
• Aoyagi, Yoshihiro
• Miki, Izumi
• Uchigata, Hiroshi
• Kuramoto, Naomi
• Fuse, Nozomu
• Yoshino, Takayuki
• Ohtsu, Atsushi

Titel

Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data

Ist Teil von

• Clinical colorectal cancer, 2023-03, Vol.22 (1), p.45-52

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• •Usage of real-world data (RWD) for clinical implementation is gaining popularity.•Use of SCRUM-Japan Registry for the phase II TRIUMPH study was investigated•We've paved way for RWD approval in Japan•Future steps for building regulatory-grade registries and using RWD must be defined Utilizing real-world data (RWD) for effective clinical implementation is becoming more and more appealing as the cost of drug development rises, especially for patients with rare diseases and rare molecular subtypes for whom conducting randomized controlled trials is challenging. If a regulatory approval methodology based on RWD as an external control group can be established, drug development for rarer fractions can be accelerated by lowering costs and time, as well as reducing physical and emotional burdens on both patients and healthcare professionals. Since 2017, we have been prospectively collecting the clinical data of standard therapies in patients with rare molecular fractions under the SCRUM-Japan Registry platform, which is a qualified registry utilized as external control data for regulatory submission. Based on the results of the phase II TRIUMPH study (UMIN000027887) and the extracted data from the SCRUM-Japan Registry, the pharmaceutical company submitted an application for pertuzumab and trastuzumab in patients with HER2-positive metastatic colorectal cancer in April 2021. Pertuzumab and trastuzumab were approved as expanded indications on March 28, 2022, as 6 cases out of 14 extracted from the SCRUM-Japan Registry were classified and utilized as “evaluation material” under the review process of the Pharmaceuticals and Medical Devices Agency (PMDA). Through the TRIUMPH study and the SCRUM-Japan Registry, we have paved the way for regulatory approval of RWD in Japan. In future, we must define the steps for constructing regulatory-grade registries and the method/process for utilizing RWD by accumulating case experiences.